Summary
Radionuclides already have a major role in the daily practice of oncology and will, undoubtedly, be of even greater importance in the future. The variety of current and potential applications is shown in tab. 1. Their major use at this time is, in the broadest sense, for ‘tumour scanning’, which includes the evaluation of specific organs for the presence of tumour (usually with different radiopharmaceuticals for each organ) and the entire body (generalized tumour searches with radiopharmaceuticals like67Ga-citrate or111In-labeled bleomycin). The clinician uses these agents in the initial evaluation of extent of tumour (staging) and in the subsequent management of the patient with cancer to assess response to treatment, to reveal early relapse, and to assist in making decisions concerning treatment. The other potential roles for radionuclides are also briefly considered in this review.
This is a preview of subscription content, log in via an institution to check access.
References
Andrews G. A., Edwards C. L.: Tumour Scanning with Gallium 67 — J. Amer. med. Ass.233, 1100, 1975.
Bagley C. M., Jr.,Thomas L. B., Johnson R. E. et al.: Diagnosis of Liver Involvement by Lymphoma: Results in 96 Consecutive Peritoneoscopies — Cancer31, 840, 1973.
Bonadonna G., Brusamdino E., Valagussa P. et al.: Adjuvant Chemotherapy with Cyclophosphamide, Methotrexate, and 5-Fluorouracil for Early Breast Cancer — New Engl. J. Med.294, 405, 1976.
Cellerino A., Filippi P. G., Chiantaretto A. et al.: Operative and Pathologic Survey of 50 Cases of Peripheral Lung Tumours Scanned with 67 Gallium — Chest64, 700, 1973.
Charkes N. D., Malmud L. S., Caswell T. et al.: Preoperative Bone Scans. Use in Women with Early Breast Cancer — J. Amer. med. Ass.233, 516. 1975.
Conn J. W., Morita R., Cohen E. L. et al.: Primary Aldosteronism: Photoscanning of Tumours after Administration of131I-19-Iodocholesterol — Arch. intern. Med.129, 417, 1972.
Davies R. J., Vernon M., Croft D. N.: Liver Snaps and the Detection of Clinically Unsuspected Liver Metastases — Lanceti, 279, 1974.
Durie B. G. M., Hellman D., O’Mara R. E. et al.: Multimodality Treatment for High Risk Thyroid Carcinoma — Proc. Amer. Ass. Cancer Res.17, 277, 1976.
Durie B. G. M., Salmon S. E.: A Clinical Staging System for Multiple Myeloma: Correlation of Measured Myeloma Cell Mass with Presenting Clinical Features, Response to Treatment, and Survival — Cancer36, 842, 1975.
Fee H. J., Prokop E. K., Cameron J. L. et al.: Liver Scanning in Patients with Suspected Abdominal Tumour — J. Amer. med. Ass.230, 1675, 1974.
Ferrant A., Rodhain J., Michaux J. L. et al.: Detection of Skeletal Involvement in Hodgkin’s Disease: A Comparison of Radiography, Bone Scanning, and Bone Marrow Biopsy in 38 Patients — Cancer35, 1346, 1975.
Fisher B., Carbone P., Economou S. G. et al.: L-Phenylalanine Mustard (L-PAM) in the Management of Primary Breast Cancer. A Report of Early Findings — New Engl. J. Med.292, 117, 1975.
Fisher E. R., Gregorio R. M., Fisher B.: The Pathology of Invasive Breast Cancer. A Syllabus Derived from Findings of the National Surgical Adjuvant Breast Project (Protocol No. 4) — Cancer36, 1, 1975.
Ghose T., Guclu A., Tai J. et al.: Antibody as Carrier of131I in Cancer Diagnosis and Treatment — Cancer36, 1646, 1975.
Greenlaw R. H., Weinstein M. B., Brill A. B. et al.:67Ga-Citrate Imaging in Untreated Malignant Lymphoma. Preliminary Report of Cooperative Group — J. nucl. Med.15, 404, 1974.
Griffin J. W., Thompson R. W., Mitchinson M. J. et al.: Lymphomatous Leptomeningitis — Amer. J. Med.51, 200, 1971.
Hansen H. H.: Should Initial Treatment of Small Cell Carcinoma Include Systemic Chemotherapy and Brain Irradiation? — Cancer chemother. Rep.4, 239, 1973.
Hoffer P. B., Lathrop K., Refetoff S. et al.: Use of Radioiodine-Labeled Anti-CEA Anti-body as a Tumor Scanning Agent — J. nucl. Med.14, 408, 1973. (Abstract)
Ichikawa T., Umezawa H., Ohashi S. et al.: Animal Experiments Confirming the Specific Effect of Bleomycin against Squamous Cell Carcinoma — In: Progress in Antimicrobial and Antineoplastic Chemotherapy. Proceedings of the 6th International Congress of Chemotherapy. Tokyo, 1969. University Park Press, Baltimore, 1970; vol. 2, p. 315.
Jones S. E.: Non-Hodgkin Lymphomas — J. Amer. med. Ass.234, 633, 1975.
Jones S. E., Durie B. G. M., Salmon S. E.: Combination Chemotherapy with Adriamycin and Cyclophosphamide for Advanced Breast Cancer — Cancer36, 90, 1975.
Jones S. E., Lilien D. L., O’Mara R. E. et al.: Indium-111 Bleomycin Tumour Scanning in Lymphoma — Med. pediat. Oncol.1, 11, 1975.
Jones S. E., Salmon S. E., Durie B. G. M.: Failure of Indium-111-Labeled Bleomycin Tumour Scanning to Predict Response to Bleomycin (NSC-125066) Treatment — Cancer chemother. Rep.58, 733, 1974.
Kaplan H. S.: Hodgkin’s Disease — Harvard University Press, Cambridge, Mass., 1972.
Kaplan H. S., Rosenberg S. A.: The Management of Hodgkin’s Disease — Cancer36, 796, 1975.
Kay D. N., McCready V. R.: Clinical Isotope Scanning Using67Ga-Citrate in the Management of Hodgkin’s Disease — Brit. J. Radiol.45, 437, 1972.
Levi J. A., O’Connell M. J., Murphy W. L. et al.: Role of67Gallium Citrate Scanning in the Management of Non-Hodgkin’s Lymphoma — Cancer36, 1690, 1975.
Lilien D. L.: The Current Status of Tumour Imaging — J. Amer. med. Ass.230, 735, 1974.
Lilien D. L., Berger H. G., Anderson D. P. et al.:111In-Chloride: A New Agent for Bone Marrow Imaging — J. nucl. Med.14, 184, 1973.
Lilien D. L., Jones S. E., O’Mara R. E. et al.: A Clinical Evaluation of Indium-111 Bleomycin as a Tumour-Imaging Agent — Cancer35, 1036, 1975.
Lipton M. J., DeNardo G. L., Silverman S. et al.: Evaluation of the Liver and Spleen in Hodgkin’s Disease. I. The Value of Hepatic Scintigraphy — Amer. J. Med.52, 356, 1972.
Lloyd R. E., Jones S. E., Salmon S. E. et al.: Combination Chemotherapy with Adriamycin (NSC-123127) and Cyclophosphamide (NSC-26271) for Solid Tumours: A Phase II Trial — Cancer Treat. Rep.60, 77, 1976.
Loeffler R. K., DiSimone R. N., Howland W. J.: Limitations of Bone Scanning in Clinical Oncology — J. Amer. med. Ass.234, 1228, 1975.
Lukes R. J., Collins R. D.: New Approaches to the Classification of the Lymphomata — Brit. J. Cancer31 (Suppl. 2), 1, 1975.
Mundy G. R., Raisz L. G., Cooper R. A. et al.: Evidence for the Secretion of an Osteoclast Stimulating Factor in Myeloma — New Engl. J. Med.291, 1041, 1974.
O’Mara R. E.: Bone Scanning in Osseous Metastatic Disease — J. Amer. med. Ass.229, 1915, 1974.
Order S. E., Bloomer W. D., Jones A. G. et al.: Radionuclide Immunoglobulin Lymphangiography: A Case Report — Cancer35, 1487, 1975.
Pochin E. F.: Thyroid Adenocarcinoma: A Functioning Tumour — Lanceti, 94, 1969.
Rosenoff S. H., Young R. C., Anderson T. et al.: Peritoneoscopy: A Valuable Staging Tool in Ovarian Carcinoma — Ann. intern. Med.83, 37, 1975.
Salmon S. E.: Progress in Adjuvant Chemotherapy of Early Breast Cancer — Ariz. Med.32, 108, 1975.
Schechter J. P., Jones S. E., Woolfenden J. M. et al.: Bone Scanning in Lymphoma — Cancer38, 1142, 1976.
Silverman S., DeNardo G. L., Glatstein E. et al.: Evaluation of the Liver and Spleen in Hodgkin’s Disease. II. The Value of Splenic Scintigraphy — Amer. J. Med.52, 362, 1972.
Turner D. A., Pinsky S. M., Gottschalk A. et al.: The Use of67Ga Scanning in the Staging of Hodgkin’s Disease — Radiology104, 97, 1972
Author information
Authors and Affiliations
Additional information
Reproduced in part fromSeminars in Nuclear Medicine 6, 331, 1976. With permission of Grune and Stratton, Inc., New York.
Rights and permissions
About this article
Cite this article
Jones, S.E. Radionuclides in oncology. La Ricerca Clin. Lab. 7, 143–159 (1977). https://doi.org/10.1007/BF02879480
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02879480